{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:06:17Z","timestamp":1792757177831,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001117","name":"amfAR, The Foundation for AIDS Research","doi-asserted-by":"publisher","award":["110068-68-RGCV"],"award-info":[{"award-number":["110068-68-RGCV"]}],"id":[{"id":"10.13039\/100001117","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","award":["VR2-173203"],"award-info":[{"award-number":["VR2-173203"]}],"id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["37521"],"award-info":[{"award-number":["37521"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["41027"],"award-info":[{"award-number":["41027"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Plasma RNAemia, delayed antibody responses and inflammation predict COVID-19 outcomes, but the mechanisms underlying these immunovirological patterns are poorly understood. We profile 782 longitudinal plasma samples from 318 hospitalized patients with\u00a0COVID-19. Integrated analysis using k-means reveals four patient clusters in a discovery cohort: mechanically ventilated critically-ill cases are subdivided into good prognosis and high-fatality clusters (reproduced in a validation cohort), while non-critical survivors segregate into high and low early antibody responders. Only the high-fatality cluster is enriched for transcriptomic signatures associated with COVID-19 severity, and each cluster has distinct RBD-specific antibody elicitation kinetics. Both critical and non-critical clusters with delayed antibody responses exhibit sustained IFN signatures, which negatively correlate with contemporaneous RBD-specific IgG levels and absolute SARS-CoV-2-specific B and CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cell frequencies. These data suggest that the \u201cInterferon paradox\u201d previously described in murine LCMV models is operative in COVID-19, with excessive IFN signaling delaying development of adaptive virus-specific immunity.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-48556-y","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T14:03:13Z","timestamp":1715868193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity"],"prefix":"10.1038","volume":"15","author":[{"given":"Elsa","family":"Brunet-Ratnasingham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2044-1180","authenticated-orcid":false,"given":"Haley E.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Labrecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4219-1824","authenticated-orcid":false,"given":"Justin","family":"B\u00e9lair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Lima-Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Pagliuzza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorie","family":"Marchitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4675-1099","authenticated-orcid":false,"given":"Michael","family":"Hultstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8852-1924","authenticated-orcid":false,"given":"Julia","family":"Niessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Cloutier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina M.","family":"Sreng Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4320-9416","authenticated-orcid":false,"given":"Nathalie","family":"Brassard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Benlarbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Pr\u00e9vost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Priya","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7956-4463","authenticated-orcid":false,"given":"G\u00e9r\u00e9my","family":"Sannier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3961-8831","authenticated-orcid":false,"given":"Amanda","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"W\u00e5gs\u00e4ter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bareke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7118-1249","authenticated-orcid":false,"given":"Hugo","family":"Zeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1976-4129","authenticated-orcid":false,"given":"Miklos","family":"Lipcsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2278-7951","authenticated-orcid":false,"given":"Robert","family":"Frithiof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3161-0402","authenticated-orcid":false,"given":"Anders","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4963-0815","authenticated-orcid":false,"given":"Sirui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9510-5646","authenticated-orcid":false,"given":"Tomoko","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8380-3615","authenticated-orcid":false,"given":"David","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0780-8593","authenticated-orcid":false,"given":"Dani","family":"Vezina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bourassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Gendron-Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima","family":"Medjahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Point","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-4782","authenticated-orcid":false,"given":"Catherine","family":"Larochelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6188-0580","authenticated-orcid":false,"given":"Alexandre","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7876-7779","authenticated-orcid":false,"given":"Janet L.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3718-1584","authenticated-orcid":false,"given":"Nathalie","family":"Arbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3746-9086","authenticated-orcid":false,"given":"J. Brent","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9747-5018","authenticated-orcid":false,"given":"Nicolas","family":"Chomont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Finzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"T\u00e9treault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9456-367X","authenticated-orcid":false,"given":"Luis","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6740-059X","authenticated-orcid":false,"given":"Guy","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4467-136X","authenticated-orcid":false,"given":"Daniel E.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"48556_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj5629","volume":"7","author":"E Brunet-Ratnasingham","year":"2021","unstructured":"Brunet-Ratnasingham, E. et al. Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. Sci. Adv. 7, eabj5629 (2021).","journal-title":"Sci. Adv."},{"key":"48556_CR2","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/S2213-2600(20)30354-4","volume":"8","author":"E Pujadas","year":"2020","unstructured":"Pujadas, E. et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir. Med. 8, e70 (2020).","journal-title":"Lancet Respir. Med."},{"key":"48556_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86500-y","volume":"11","author":"JD Jarhult","year":"2021","unstructured":"Jarhult, J. D., Hultstrom, M., Bergqvist, A., Frithiof, R. & Lipcsey, M. The impact of viremia on organ failure, biomarkers and mortality in a Swedish cohort of critically ill COVID-19 patients. Sci. Rep. 11, 7163 (2021).","journal-title":"Sci. Rep."},{"key":"48556_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","volume":"400","author":"R. C. Group.","year":"2022","unstructured":"R. C. Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet 400, 359\u2013368 (2022).","journal-title":"Lancet"},{"key":"48556_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23923-1","volume":"12","author":"R Rovito","year":"2022","unstructured":"Rovito, R. et al. Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients. Sci. Rep. 12, 19658 (2022).","journal-title":"Sci. Rep."},{"key":"48556_CR6","doi-asserted-by":"publisher","first-page":"155389","DOI":"10.1016\/j.cyto.2020.155389","volume":"138","author":"S Bulow Anderberg","year":"2021","unstructured":"Bulow Anderberg, S. et al. Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. Cytokine 138, 155389 (2021).","journal-title":"Cytokine"},{"key":"48556_CR7","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","volume":"26","author":"AG Laing","year":"2020","unstructured":"Laing, A. G. et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med. 26, 1623\u20131635 (2020).","journal-title":"Nat. Med."},{"key":"48556_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","volume":"584","author":"C Lucas","year":"2020","unstructured":"Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463\u2013469 (2020).","journal-title":"Nature"},{"key":"48556_CR9","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"R. C. Group.","year":"2021","unstructured":"R. C. Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637\u20131645 (2021).","journal-title":"Lancet"},{"key":"48556_CR10","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"R-C Investigators","year":"2021","unstructured":"Investigators, R.-C. et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N. Engl. J. Med. 384, 1491\u20131502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"48556_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RC Group","year":"2021","unstructured":"Group, R. C. et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693\u2013704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"48556_CR12","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","volume":"370","author":"P Bastard","year":"2020","unstructured":"Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).","journal-title":"Science"},{"key":"48556_CR13","doi-asserted-by":"publisher","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","volume":"370","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020).","journal-title":"Science"},{"key":"48556_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"WHOST Consortium","year":"2021","unstructured":"Consortium, W. H. O. S. T. et al. Repurposed antiviral drugs for Covid-19\u2014interim WHO solidarity trial results. N. Engl. J. Med. 384, 497\u2013511 (2021).","journal-title":"N. Engl. J. Med."},{"key":"48556_CR15","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S2213-2600(21)00384-2","volume":"9","author":"AC Kalil","year":"2021","unstructured":"Kalil, A. C. et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 9, 1365\u20131376 (2021).","journal-title":"Lancet Respir. Med."},{"key":"48556_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18854-2","volume":"11","author":"R Nienhold","year":"2020","unstructured":"Nienhold, R. et al. Two distinct immunopathological profiles in autopsy lungs of COVID-19. Nat. Commun. 11, 5086 (2020).","journal-title":"Nat. Commun."},{"key":"48556_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03362-y","volume":"24","author":"S Asif","year":"2020","unstructured":"Asif, S. et al. Weak anti-SARS-CoV-2 antibody response is associated with mortality in a Swedish cohort of COVID-19 patients in critical care. Crit. Care 24, 639 (2020).","journal-title":"Crit. Care"},{"key":"48556_CR18","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.cell.2020.10.052","volume":"183","author":"T Zohar","year":"2020","unstructured":"Zohar, T. et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell 183, 1508\u20131519.e1512 (2020).","journal-title":"Cell"},{"key":"48556_CR19","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996\u20131012.e1019 (2020).","journal-title":"Cell"},{"key":"48556_CR20","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1126\/science.abc6261","volume":"369","author":"PS Arunachalam","year":"2020","unstructured":"Arunachalam, P. S. et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 369, 1210\u20131220 (2020).","journal-title":"Science"},{"key":"48556_CR21","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.cell.2021.02.018","volume":"184","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. Cell 184, 1836\u20131857.e1822 (2021).","journal-title":"Cell"},{"key":"48556_CR22","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/s41587-019-0336-3","volume":"37","author":"KR Moon","year":"2019","unstructured":"Moon, K. R. et al. Visualizing structure and transitions in high-dimensional biological data. Nat. Biotechnol. 37, 1482\u20131492 (2019).","journal-title":"Nat. Biotechnol."},{"key":"48556_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1126\/science.abg0928","volume":"374","author":"HE Randolph","year":"2021","unstructured":"Randolph, H. E. et al. Genetic ancestry effects on the response to viral infection are pervasive but cell type specific. Science 374, 1127\u20131133 (2021).","journal-title":"Science"},{"key":"48556_CR24","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"48556_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/bioinformatics\/btp101","volume":"25","author":"G Bindea","year":"2009","unstructured":"Bindea, G. et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25, 1091\u20131093 (2009).","journal-title":"Bioinformatics"},{"key":"48556_CR26","doi-asserted-by":"publisher","first-page":"eabc8511","DOI":"10.1126\/science.abc8511","volume":"369","author":"D Mathew","year":"2020","unstructured":"Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369, eabc8511 (2020).","journal-title":"Science"},{"key":"48556_CR27","doi-asserted-by":"publisher","first-page":"10514","DOI":"10.1128\/JVI.79.16.10514-10527.2005","volume":"79","author":"DG Brooks","year":"2005","unstructured":"Brooks, D. G., Teyton, L., Oldstone, M. B. & McGavern, D. B. Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J. Virol. 79, 10514\u201310527 (2005).","journal-title":"J. Virol."},{"key":"48556_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.1235214","volume":"340","author":"JR Teijaro","year":"2013","unstructured":"Teijaro, J. R. et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207\u2013211 (2013).","journal-title":"Science"},{"key":"48556_CR29","doi-asserted-by":"publisher","first-page":"111013","DOI":"10.1016\/j.celrep.2022.111013","volume":"39","author":"M Nayrac","year":"2022","unstructured":"Nayrac, M. et al. Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. Cell Rep. 39, 111013 (2022).","journal-title":"Cell Rep."},{"key":"48556_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19057-5","volume":"11","author":"J Fajnzylber","year":"2020","unstructured":"Fajnzylber, J. et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat. Commun. 11, 5493 (2020).","journal-title":"Nat. Commun."},{"key":"48556_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","volume":"386","author":"RL Gottlieb","year":"2022","unstructured":"Gottlieb, R. L. et al. Early Remdesivir to prevent progression to severe Covid-19 in outpatients. N. Engl. J. Med. 386, 305\u2013315 (2022).","journal-title":"N. Engl. J. Med."},{"key":"48556_CR32","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","volume":"385","author":"DM Weinreich","year":"2021","unstructured":"Weinreich, D. M. et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N. Engl. J. Med. 385, e81 (2021).","journal-title":"N. Engl. J. Med."},{"key":"48556_CR33","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa2033130","volume":"384","author":"A.-T. L.-C. S. Group.","year":"2021","unstructured":"A.-T. L.-C. S. Group. et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N. Engl. J. Med. 384, 905\u2013914 (2021).","journal-title":"N. Engl. J. Med."},{"key":"48556_CR34","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","volume":"399","author":"R. C. Group.","year":"2022","unstructured":"R. C. Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399, 665\u2013676 (2022).","journal-title":"Lancet"},{"key":"48556_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","volume":"29","author":"S Crotty","year":"2011","unstructured":"Crotty, S. Follicular helper CD4 T cells (TFH). Annu Rev. Immunol. 29, 621\u2013663 (2011).","journal-title":"Annu Rev. Immunol."},{"key":"48556_CR36","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.abc2061","volume":"369","author":"J Major","year":"2020","unstructured":"Major, J. et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science 369, 712\u2013717 (2020).","journal-title":"Science"},{"key":"48556_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41586-022-04421-w","volume":"603","author":"JD Domizio","year":"2022","unstructured":"Domizio, J. D. et al. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature 603, 145\u2013151 (2022).","journal-title":"Nature"},{"key":"48556_CR38","doi-asserted-by":"publisher","first-page":"e20191220","DOI":"10.1084\/jem.20191220","volume":"217","author":"N Palacio","year":"2020","unstructured":"Palacio, N. et al. Early type I IFN blockade improves the efficacy of viral vaccines. J. Exp. Med. 217, e20191220 (2020).","journal-title":"J. Exp. Med."},{"key":"48556_CR39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1126\/science.1235208","volume":"340","author":"EB Wilson","year":"2013","unstructured":"Wilson, E. B. et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202\u2013207 (2013).","journal-title":"Science"},{"key":"48556_CR40","doi-asserted-by":"publisher","unstructured":"Hoang, T. N. et al. Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques. bioRxiv, https:\/\/doi.org\/10.1101\/2022.10.21.512606 (2022).","DOI":"10.1101\/2022.10.21.512606"},{"key":"48556_CR41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nri3461","volume":"13","author":"M Papatriantafyllou","year":"2013","unstructured":"Papatriantafyllou, M. The interferon paradox. Nat. Rev. Immunol. 13, 392\u2013393 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"48556_CR42","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/nature13554","volume":"511","author":"NG Sandler","year":"2014","unstructured":"Sandler, N. G. et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511, 601\u2013605 (2014).","journal-title":"Nature"},{"key":"48556_CR43","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","volume":"591","author":"E Pairo-Castineira","year":"2021","unstructured":"Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in COVID-19. Nature 591, 92\u201398 (2021).","journal-title":"Nature"},{"key":"48556_CR44","doi-asserted-by":"publisher","first-page":"eabd1554","DOI":"10.1126\/sciimmunol.abd1554","volume":"5","author":"JS Lee","year":"2020","unstructured":"Lee, J. S. et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci. Immunol. 5, eabd1554 (2020).","journal-title":"Sci. Immunol."},{"key":"48556_CR45","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036\u20131045.e1039 (2020).","journal-title":"Cell"},{"key":"48556_CR46","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s40121-022-00633-9","volume":"11","author":"D Jhuti","year":"2022","unstructured":"Jhuti, D. et al. Interferon treatments for SARS-CoV-2: challenges and opportunities. Infect. Dis. Ther. 11, 953\u2013972 (2022).","journal-title":"Infect. Dis. Ther."},{"key":"48556_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"48556_CR48","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.1016\/j.xcrm.2020.100126","volume":"1","author":"J Prevost","year":"2020","unstructured":"Prevost, J. et al. Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike. Cell Rep. Med. 1, 100126 (2020).","journal-title":"Cell Rep. Med."},{"key":"48556_CR49","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1126\/science.abb7269","volume":"368","author":"M Yuan","year":"2020","unstructured":"Yuan, M. et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630\u2013633 (2020).","journal-title":"Science"},{"key":"48556_CR50","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/14786440109462720","volume":"2","author":"K Pearson","year":"1901","unstructured":"Pearson, K. LIII. On lines and planes of closest fit to systems of points in space. Lond. Edinb. Dublin Philos. Mag. J. Sci. 2, 559\u2013572 (1901).","journal-title":"Lond. Edinb. Dublin Philos. Mag. J. Sci."},{"key":"48556_CR51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1109\/TIT.1982.1056489","volume":"28","author":"SP Lloyd","year":"1982","unstructured":"Lloyd, S. P. Least squares quantization in PCM. IEEE Trans. Inf. Theory 28, 129\u2013136 (1982).","journal-title":"IEEE Trans. Inf. Theory"},{"key":"48556_CR52","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa, F. et al. Scikit-learn: machine learning in Python. J. Mach. Learn. Res. 12, 2825\u20132830 (2011).","journal-title":"J. Mach. Learn. Res."},{"key":"48556_CR53","doi-asserted-by":"crossref","unstructured":"Burkhardt, D. B. et al. Quantifying the effect of experimental perturbations at single-cell resolution. Nat. Biotechnol. 39, 619\u2013629 (2021).","DOI":"10.1038\/s41587-020-00803-5"},{"key":"48556_CR54","doi-asserted-by":"crossref","unstructured":"Saravanan, V., Berman, G. J. & Sober, S. J. Application of the hierarchical bootstrap to multi-level data in neuroscience. Neuron Behav. Data Anal. Theory 3, 1\u201325 (2020).","DOI":"10.1101\/819334"},{"key":"48556_CR55","doi-asserted-by":"crossref","unstructured":"Efron, B. & Tibshirani, R. J. An Introduction to the Bootstrap. (CRC Press, 1994).","DOI":"10.1201\/9780429246593"},{"key":"48556_CR56","doi-asserted-by":"publisher","first-page":"e0146021","DOI":"10.1371\/journal.pone.0146021","volume":"10","author":"C Ritz","year":"2015","unstructured":"Ritz, C., Baty, F., Streibig, J. C. & Gerhard, D. Dose-response analysis using R. PLoS One 10, e0146021 (2015).","journal-title":"PLoS One"},{"key":"48556_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. Embnet. J. 17, 10\u201312 (2011).","journal-title":"Embnet. J."},{"key":"48556_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"48556_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).","journal-title":"Genome Biol."},{"key":"48556_CR60","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"48556_CR61","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.09.025","volume":"167","author":"Y Nedelec","year":"2016","unstructured":"Nedelec, Y. et al. Genetic ancestry and natural selection drive population differences in immune responses to pathogens. Cell 167, 657\u2013669 e621 (2016).","journal-title":"Cell"},{"key":"48556_CR62","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.1073\/pnas.1530509100","volume":"100","author":"JD Storey","year":"2003","unstructured":"Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. Proc. Natl Acad. Sci. USA 100, 9440\u20139445 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"48556_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 14, 7 (2013).","journal-title":"BMC Bioinforma."},{"key":"48556_CR64","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48556-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48556-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48556-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T02:12:14Z","timestamp":1730254334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48556-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["48556"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-48556-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.06.14.23290814","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"1 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.B.R. has served as an advisor to GlaxoSmithKline and Deerfield Capital. T.N. has received speaking fee from Boehringer Ingelheim for talks unrelated to this research. D.E.K. has served as an advisor to AstraZeneca. These agencies had no role in the design, implementation, or interpretation of this study. The authors declare that they have no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4177"}}